Join the Oncology Voice Network. Join for Free
Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective
patient participation in scientific publishing medical communications and patient engagement roles of patients in research communicating with patient advocates patient education in research patient engagement podcast scientific publishing process

Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective


Share This Article


Summary

Continuing our look at increasing patient participation in the scientific publication process, this episode of InformED will look at the process from a medical communications perspective. Our guests discuss questions to think through during the planning stages including: the different roles that patients can take, how to best communicate with patients and patient advocates, and education they may need to fully engage in the process.

Guest host Kelly Soldavin, Senior Editor at Taylor & Francis Group is joined by Jacqui Oliver, Patient Partnership Director, Scientific at Envision Pharma Group and Sarah Griffiths, Communications Director, Patient Engagement at Oxford PharmaGenesis to for this second episode in a series of patient engagement in scientific publishing podcasts.

Click for Source
patient participation in scientific publishing, medical communications and patient engagement, roles of patients in research, communicating with patient advocates, patient education in research, patient engagement podcast, scientific publishing process

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Value assessment frameworks in oncology: championing concordance through shared standards
OVN Avatar M. Bertagnolli and J. Tabernero

Value assessment frameworks in oncology: championing concordance through shared standards

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Explore OVN